Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 9,417 shares, a growth of 116.0% from the August 15th total of 4,359 shares. Based on an average trading volume of 10,401 shares, the days-to-cover ratio is presently 0.9 days.
Defence Therapeutics Price Performance
Shares of Defence Therapeutics stock opened at $0.34 on Monday. The stock’s fifty day simple moving average is $0.33 and its 200 day simple moving average is $0.37. Defence Therapeutics has a 12 month low of $0.25 and a 12 month high of $0.78.
Defence Therapeutics Company Profile
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
See Also
- Five stocks we like better than Defence Therapeutics
- Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains
- Digging for Value: Alpha Metallurgical Resources Insider Buys Big
- Smart Money Shifts: U.S. Bancorp Pairs Tech With Yield
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
